Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: A phase ii trial of the sarah cannon oncology research consortium

Clinical Breast Cancer

Volumn 11, Issue 3, 2011, Pages 146-152

  Yardley, Denise A ^a,b   Burris, Howard A ^a,b   Clark, Bobby L ^a   Shipley, Dianna ^b   Rubin, Mark ^c   Barton Jr , John ^b   Arrowsmith, Edward ^d   Hainsworth, John D ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^d Chattanooga Oncology Hematology Associates   (United States)

Author keywords

Bevacizumab; Hormonal therapy; Metastatic breast cancer

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; TRASTUZUMAB; WARFARIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESTRADIOL; MONOCLONAL ANTIBODY; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTHRALGIA; ARTICLE; BLEEDING; BREAST CANCER; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; COUGHING; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FISTULA; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL THERAPY; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; LIVER FUNCTION TEST; LOADING DRUG DOSE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUROPATHY; POSTMENOPAUSE; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING; WOUND DEHISCENCE; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HORMONE SUBSTITUTION; METASTASIS; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TRIAZOLES;

EID: 80053400728     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.03.010     Document Type: Article

References (25)

1. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83:1142-52. (Pubitemid 28419067)
2. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-61. (Pubitemid 28135586)
3. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18:3748-57.
4. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18:3758-67.
5. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-606. (Pubitemid 32451796)
6. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in post-menopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26:4883-90.
7. Howell A, Robertson JFR, Albano JQ, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20:3396-403.
8. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20:3386-95.
9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
10. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO. J Clin Oncol 26: 43s, 2008 (abstract LBA2011).
11. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy, with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2009; 27:42s (abstract 1005).
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76. (Pubitemid 36749215)
13. Nakamura J, Savinov A, Lu Q, et al. Estrogen regulates vascular endothelial growth/ permeability factor expression in 7,12-dimethylbez(a) anthacene-induced rat mammary tumors. Endocrinology 1996; 137:5589-96. (Pubitemid 26423128)
14. Manders P, Beex LV, Tjan-Heijnen VC, et al. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 2003; 98:2125-32. (Pubitemid 37392415)
15. Linderholm B, Grankvist K, Wilking N, et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first-relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18: 1423-31. (Pubitemid 30205387)
16. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2 -positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TanDEM study. J Clin Oncol 2009; 27:5529-37.
17. Johnston S, Pippen J, Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor positive metastatic breast cancer. J Clin Oncol 2009; 27:5538-46.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
19. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979.
20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
21. Massarweh S, Schiff R. Unraveling the mechanism of endocrine resistance in breast cancer: New therapeutic opportunities. Clin Cancer Res 2007; 13:1950-4. (Pubitemid 46649859)
22. Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy in breast cancer. Clin Cancer Res 2005; 11:865s-70s. (Pubitemid 40111098)
23. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95:10820-5. (Pubitemid 28413152)
24. DiLeo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28:4594-600.
25. Traina TA, Rugo HS, Caravelli JF, et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 2009; 28:628-33.